Morning Movers 9/24: LBIX, CRXX, EFOI, HLCS, GNVC, VICL Higher; CHTP, CNXT, HERO, RAD, PSEC Lower Sep 24, 2009 09:35AM

Chelsea Therapeutics (Nasdaq: CHTP) 76.5% LOWER; announced top-line results from Study 302, the first of two Phase III trials of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension did not show statistically significant improvement versus placebo. Click here for the full report.

Leading Brands, Inc. (Nasdaq: LBIX) 37.9% HIGHER; reports Q2 EPS of $0.04, compared to a loss of $0.01 in the same quarter last year. Revenue for the quarter was $6.62 million, versus $5.89 million in Q208.

CombinatoRx, Incorporated (NASDAQ: CRXX) 17.9% HIGHER; today announced that the U.S. FDA in a joint meeting of its Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management Advisory Committee heard presentations and public testimony and discussed the New Drug Application submitted by Neuromed for EXALGOTM (hydromorphone HCl extended release) tablets, seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients ...